A New Hope for Pancreatic Cancer: PARP Inhibitors in Tumors With BRCA Mutations

Review this CCO on-demand Webcast with downloadable slides from the 2019 ASCO GI live satellite symposium.
John L. Marshall, MD
Program Director
Tanios Bekaii-Saab
Tanios Bekaii-Saab, MD, FACP
Eileen M. O'Reilly, MD

Downloadable Slidesets

In this downloadable slideset, John L. Marshall, MD, reviews mutations associated with DNA damage repair deficiencies and the mechanism of PARP inhibition

John L. Marshall, MD
Program Director
Released: January 17, 2019

In this downloadable slideset, Eileen M. O’Reilly, MD, reviews key data for PARP inhibition in pancreatic cancer

Eileen M. O'Reilly, MD Released: January 17, 2019

In this downloadable slideset, Tanios Bekaii-Saab, MD, FACP, reviews future directions in DNA damage repair deficient pancreatic cancer, including ongoing clinical trials

Tanios Bekaii-Saab Tanios Bekaii-Saab, MD, FACP Released: January 17, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue